Analysis of long-term survivors with cardiac AL amyloidosis

DOI Web Site PubMed
  • KAGAWA Kumiko
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • MAEDA Yusaku
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • OURA Masahiro
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • SOGABE Kimiko
    Department of Internal Medicine, Anan Kyoei Hospital
  • FUJINO Hikaru
    Department of Internal Medicine, Anan Kyoei Hospital
  • TAKAHASHI Mamiko
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • MARUHASHI Tomoko
    Department of Internal Medicine, Tokushima Prefecture Naruto Hospital
  • IWASA Masami
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • UDAKA Kengo
    Department of Hematology, Tokushima Prefectural Central Hospital
  • HARADA Takeshi
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • ISE Takayuki
    Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital
  • FUJII Shiro
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • NAKAMURA Shingen
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School
  • MIKI Hirokazu
    Department of Cardiovascular Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School
  • YAGI Shusuke
    Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital
  • TAKEUCHI Kyoko
    Department of Internal Medicine, Tokushima Municipal Hospital
  • OZAKI Shuji
    Department of Hematology, Tokushima Prefectural Central Hospital
  • ABE Masahiro
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School

Bibliographic Information

Other Title
  • 治療後長期生存が得られた心不全合併ALアミロイドーシス症例の検討
  • 臨床研究 治療後長期生存が得られた心不全合併ALアミロイドーシス症例の検討
  • リンショウ ケンキュウ チリョウ ゴ チョウキ セイゾン ガ エラレタ シンフゼン ガッペイ AL アミロイドーシス ショウレイ ノ ケントウ

Search this article

Description

<p>Cardiac AL amyloidosis (CA) is generally known as a severe disease with very poor prognosis. Here we retrospectively examined seven patients with CA in our cohort who achieved long-term survival. All six patients who underwent high-dose melphalan and autologous stem cell transplantation (ASCT) survived for >3 years, whereas four patients survived for >5 years. Patients who underwent ASCT had prompt hematological responses, and five patients showed organ responses. ASCT helps to achieve a quick and deep hematological response required for long-term survival in patients with CA. New agents have been implemented for the treatment of CA. However, the risks and benefits of each treatment modality should be considered according to patient condition, thus making the best use of ASCT in combination with new agents for the treatment of CA.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 58 (11), 2197-2204, 2017

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top